Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Parkinson’S Disease and Covid-19: A Systematic Review and Meta-Analysis Publisher Pubmed



Khoshnood RJ1 ; Zali A1 ; Tafreshinejad A1 ; Ghajarzadeh M2, 3 ; Ebrahimi N4 ; Safari S1 ; Mirmosayyeb O5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
  4. 4. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Neurological Sciences Published:2022


Abstract

Background: Patients with Parkinson’s disease (PD) are at higher risk of COVID-19 infection as most of them are at older age. The goal of this study is to update the pooled prevalence of COVID-19 infection in patients with PD. Methods: Two researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and also gray literature including references of the included studies which were published before September 2021. We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, number with COVID-19, symptoms, hospitalization, and death. Results: We found 1693 articles by literature search; after deleting duplicates, 798 remained. Thirty articles remained for meta-analysis. The pooled prevalence of COVID-19 infection in PD cases was 5% (95%CI: 4–6%) (I2 = 98.1%, P < 0.001). The pooled prevalence of fever in cases with PD was 4% (95%CI: 2–6%) (I2 = 96%, P < 0.001). The pooled prevalence of cough in cases with PD was 3% (95%CI: 2–4%) (I2 = 95.9%, P < 0.001). The pooled prevalence of hospitalization in cases with COVID-19 infection was 49% (95%CI: 29–52%) (I2: 93.5%, P < 0.001). The pooled prevalence of mortality in COVID-19 cases was 12% (95%CI: 10–14%) (I2 = 97.6%, P < 0.001). Conclusion: The results of this systematic review and meta-analysis show that the pooled prevalence of COVID-19 infection in PD cases is 5% besides hospitalization and mortality rates which are 49% and 12%. © 2021, Fondazione Societa Italiana di Neurologia.
Related Docs
1. Vulnerability of Parkinson's Patients to Covid-19 and Its Consequences and Effects on Them: A Systematic Review, Parkinson's Disease (2023)
2. Chronic Neurological Diseases and Covid-19: Associations and Considerations, Translational Neuroscience (2020)
3. The Association Between Food Insecurity Status and Covid-19 in an Iranian Population: A Case–Control Study, Journal of Public Health (Germany) (2024)
4. Investigating How Interleukin 6 Serum Level, Blood Group Type, and Underlying Diseases Are Associated in Patients Admitted to the Covid-19 Intensive Care Unit: A Retrospective Study, Open Public Health Journal (2023)
5. Covid-19 Vaccines and Patients With Multiple Sclerosis: Willingness, Unwillingness and Hesitancy: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
Experts (# of related papers)
Vajiheh Aghamollaii (1)
Leila Shahmoradi (1)